ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2-care pathways, treatment, and follow-up.

The Task Force for the management of COVID-19, of the European Society of Cardiology (2022). ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2-care pathways, treatment, and follow-up. European heart journal, 43(11), pp. 1059-1103. Oxford University Press 10.1093/eurheartj/ehab697

[img] Text
ehab697.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (2MB)

AIMS

Since its emergence in early 2020, the novel severe acute respiratory syndrome coronavirus 2 causing coronavirus disease 2019 (COVID-19) has reached pandemic levels, and there have been repeated outbreaks across the globe. The aim of this two part series is to provide practical knowledge and guidance to aid clinicians in the diagnosis and management of cardiovascular (CV) disease in association with COVID-19.

METHODS AND RESULTS

A narrative literature review of the available evidence has been performed, and the resulting information has been organized into two parts. The first, which was reported previously, focused on the epidemiology, pathophysiology, and diagnosis of CV conditions that may be manifest in patients with COVID-19. This second part addresses the topics of: care pathways and triage systems and management and treatment pathways, both of the most commonly encountered CV conditions and of COVID-19; and information that may be considered useful to help patients with CV disease (CVD) to avoid exposure to COVID-19.

CONCLUSION

This comprehensive review is not a formal guideline but rather a document that provides a summary of current knowledge and guidance to practicing clinicians managing patients with CVD and COVID-19. The recommendations are mainly the result of observations and personal experience from healthcare providers. Therefore, the information provided here may be subject to change with increasing knowledge, evidence from prospective studies, and changes in the pandemic. Likewise, the guidance provided in the document should not interfere with recommendations provided by local and national healthcare authorities.

Item Type:

Journal Article (Review Article)

Division/Institute:

04 Faculty of Medicine > Department of Cardiovascular Disorders (DHGE) > Clinic of Cardiology

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1522-9645

Publisher:

Oxford University Press

Language:

English

Submitter:

Nadia Biscozzo

Date Deposited:

20 Jan 2022 14:26

Last Modified:

16 Mar 2022 00:12

Publisher DOI:

10.1093/eurheartj/ehab697

PubMed ID:

34791154

Additional Information:

Fabien Praz is a member of the Task Force for the management of COVID-19 of the European Society of Cardiology.

Uncontrolled Keywords:

ACE2 Acute coronary syndromes Arrhythmias Biomarkers COVID-19 Cardiogenic shock Heart failure Myocarditis Pulmonary embolism Thrombosis Venous thromboembolism

BORIS DOI:

10.48350/163246

URI:

https://boris.unibe.ch/id/eprint/163246

Actions (login required)

Edit item Edit item
Provide Feedback